Readout - Prime Minister Carney meets with President of France Emmanuel Macron Français
KANANASKIS, AB, June 16, 2025 /CNW/ - Today, the Prime Minister, Mark Carney, met with the President of France, Emmanuel Macron, at the 2025 G7 Leaders' Summit in Kananaskis, Alberta.
Canada and France have a long shared history and a commitment to protecting common bonds in our culture and the French language.
Building on Prime Minister Carney's visit to France earlier this year, the two leaders discussed their ongoing work to strengthen trade and commercial ties and deliver prosperity for Canada and France alike.
Prime Minister Carney and President Macron discussed bolstering co-operation on shared priorities such as critical minerals, energy security, bilateral investment, artificial intelligence, and quantum technology.
The leaders welcome the announcement today of a deal between LOT Polish Airlines and Airbus, which includes the purchase of 20 A220-100 and 20 A220-300 aircraft. The aircraft are designed and developed in Canada, and manufactured in Mirabel, Quebec, by Airbus, working with Canadian supply chain partners. This deal will support thousands of good-paying jobs in Canada and France.
Prime Minister Carney and President Macron also emphasized the growing partnership between Canada and France on cybersecurity and intelligence sharing. They welcome the new memorandum of understanding signed on June 13 to increase exchanges related to intelligence between our two countries.
The leaders discussed their support for Ukraine's sovereignty, the imperative of an immediate ceasefire in Gaza, and the situation in Haiti. They agreed to remain in close contact.
This document is also available at https://pm.gc.ca
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
43 minutes ago
- Cision Canada
Johnson & Johnson Launches New TECNIS Odyssey Next-Generation Intraocular Lens in Europe, the Middle East, and Canada Offering Cataract Patients Precise Vision at Every Distance in Any Lighting*†‡1,6
The new full visual range* 1 IOL enables 93% of patients to become free from glasses at all distances.** 2 *** With best-in-class image contrast and low-light performance, #~3,4,5 TECNIS Odyssey IOL expands the Johnson & Johnson portfolio of advanced Presbyopia Correction IOLs. TECNIS Odyssey IOL enables surgeons to deliver consistent and reliable patient outcomes. ∫ 7,15 This content is intended for Healthcare Professionals only, not for the general public. JACKSONVILLE, Fla., June 17, 2025 /CNW/ -- Johnson & Johnson, § a global leader in eye health, announced today that it is expanding its portfolio of presbyopia-correcting intraocular lenses (PC - IOL) with the roll-out of TECNIS Odyssey IOL in Europe, the Middle East, and Canada. The new full visual range *1 IOL offers high-quality and continuous vision with unmatched range. $6,16 This will allow patients to see clearly from far to near and in between, minimizing their need for glasses. ‡+2,6,7 Built on the industry-leading TECNIS platform, combining advanced optics and proprietary materials, TECNIS Odyssey IOL offers consistently clear, high-contrast vision. "TECNIS Odyssey IOL is the fastest growing PC-IOL in the United States, ^ and we are excited to be making it available to more patients around the world. It addresses a significant unmet need for cataract patients seeking greater spectacle independence. + Now – together with TECNIS PureSee – TECNIS Odyssey IOL elevates the strength and depth of our global IOL portfolio, meeting the diverse needs of today's aging population," said Peter Menziuso, Company Group Chairman, Vision, Johnson & Johnson. Currently, an estimated 94 million people aged 50 years and over have moderate-to-severe distance vision impairment or blindness that could be corrected through lens replacement surgery. 8 These figures are projected to increase, since presbyopia and cataract development are part of the aging process. Presbyopia is a progressive eye condition that makes it difficult to focus on close objects and usually becomes noticeable around 40 years of age. 9 Full visual range IOLs provide the opportunity to correct presbyopia at the time of lens replacement surgery. "From my early experience, what sets the TECNIS Odyssey IOL apart, is its ability to deliver consistent visual outcomes across a wide range of patients, due to its advanced design with higher tolerance to residual refractive error," ∫ 7,11 said Professor Beatrice Cochener-Lamard, Head of the Ophthalmology Department at Brest University Hospital in France. ^^^ TECNIS Odyssey IOL is the latest innovation for those seeking greater visual freedom – offering: Precise vision: TECNIS Odyssey IOL provides crisp and clear vision, allowing patients to see with clarity at every distance 6 - whether they are reading, driving or engaging in daily activities. 94% of patients were satisfied with their overall vision without glasses. &****12 At every distance: Its unique, freeform diffractive surface was designed to eliminate the gaps between near, intermediate and far distances, and offer continuous, uninterrupted vision at all distances. †‡6 96% of patients were satisfied with reading a smartphone or tablet, &****13 and 97% were satisfied with distance vision. &****12 In any lighting: Engineered to minimize night vision disturbances – fewer halos and glare #14 – TECNIS Odyssey IOL provides better image quality than PanOptix day and night, ##3,4,5 for a more comfortable night-time experience. 92% of patients were satisfied with their ability to see steps and read street signs at night. &****13 With a variety of options for different visual needs and lifestyles, the TECNIS platform empowers more patients to find the right solution. The Johnson & Johnson portfolio of advanced Presbyopia Correction IOLs available in Europe, the Middle East, Canada, and Japan now includes both TECNIS Odyssey IOL and TECNIS PureSee IOL. TECNIS Odyssey IOL, the full range of vision IOL, is also available in the US, Puerto Rico, and Japan. TECNIS PureSee IOL, the purely refractive, extended depth of focus IOL, is also available across APAC and Latin America. TECNIS PureSee has not received PMA Approval in the U.S. For more patient information and tools please visit Visit us at and and follow Johnson & Johnson | Vision on LinkedIn. About Vision at Johnson & Johnson Johnson & Johnson has a deep legacy in developing transformational new products that improve the health of patients' eyes. We have a bold ambition: Vision Made Possible – improving sight for more than 40 million people each year. Through cutting-edge innovation, expertise in material and optical science, and advanced technologies, we are revolutionizing the way people see and experience the world. Visit us at follow @JNJVision on Twitter, Johnson & Johnson | Vision on LinkedIn, and @JNJVision on Facebook. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more about our MedTech sector's global scale and deep expertise in cardiovascular, orthopedics, surgery and vision solutions at Follow us at @JNJMedTech and on LinkedIn. Johnson & Johnson Surgical Vision, Inc. is part of Johnson & Johnson. Cautions Concerning Forward-Looking Statements This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding the launch of TECNIS Odyssey™ intraocular lens. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: uncertainty of commercial success; challenges to patents; competition, including technological advances, new products and patents attained by competitors; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; changes to applicable laws and regulations, including global health care reforms; changes in behavior and spending patterns of purchasers of health care products and services; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. Footnotes *According to ISO 11979-7:2024, based on the clinical study of the parent IOL **(n=82) 1 month results. Q: "Was the patient wearing any spectacles or contact lenses since the surgery?" Six subjects 6/82 (5 subjects for near, 1 subject for both distance and near); ***Based on 1-month postoperative data from a multicenter, retrospective, real-world clinical study in the U.S. evaluating visual and patient-reported outcomes from subjects bilaterally implanted with TECNIS Odyssey™ IOL (n=96). ****Based on 3-month postoperative data from a multicenter, observational clinical study in the U.S. evaluating visual and patient-reported outcomes from subjects bilaterally implanted with TECNIS Odyssey™ IOL (n=33). ¶based on pre-clinical bench testing. The third-party trademarks used herein are the trademarks of their respective owners. ∫compared to TECNIS Synergy™ and TECNIS™ Multifocal IOLs based on pre-clinical bench testing #compared to PanOptix ® based on pre-clinical bench testing ##compared to leading competitor full visual range IOLs based on pre-clinical bench testing (white light MTF at 50 c/mm measured for 3mm & 5mm pupil in the ACE model) §Johnson & Johnson represents the products and services of Johnson & Johnson Surgical Vision, Inc., Johnson & Johnson Vision Care, Inc., and the affiliates of both. †continuous 20/25 or better ‡based on pre-clinical bench testing ^based on Market Scope's estimated procedure for 2024 vs 2023 ^^^Professor Beatrice Cochener-Lamard is a paid consultant of Johnson & Johnson MedTech ~Compared to TECNIS SYNERGY™ based on bench testing +Individual results will vary. Some TECNIS Odyssey™ IOL patients may require spectacles post-surgery. -Results may vary. Consult your doctor to determine the lens options that are right for you. $Compared to PanOptix ® based on bench testing and head-to-head clinical studies of parent lens &Values rounded to the nearest 1% Indication and safety information in regions where these products are available for use is included below. Please note indications may differ based on region. Full safety information is available hyperlinked below. IN THE UNITED KINGDOM The promoted product is a medical device. For healthcare professionals only. Please reference the Instructions for Use for a complete list of Indications and Important Safety Information and contact our specialists in case of any question. IN CANADA INDICATIONS AND IMPORTANT SAFETY INFORMATION FOR TECNIS ODYSSEY™ IOL WITH TECNIS SIMPLICITY™ DELIVERY SYSTEM, MODEL DRN00V AND TECNIS ODYSSEY™ TORIC II IOL WITH TECNIS SIMPLICITY™ DELIVERY SYSTEM, MODELS DRT100, DRT150, DRT225, DRT300, DRT375, IN CANADA: Rx Only INDICATIONS FOR USE: The TECNIS SIMPLICITY™ Delivery System is used to fold and assist in inserting the TECNIS Odyssey™ IOL which is indicated for primary implantation for the visual correction of aphakia in adult patients with or without presbyopia, in whom a cataractous lens has been removed. The TECNIS SIMPLICITY™ Delivery System is used to fold and assist in inserting the TECNIS Odyssey™ Toric II IOLs which are indicated for primary implantation for the visual correction of aphakia and pre-existing corneal astigmatism in adult patients with or without presbyopia, in whom a cataractous lens has been removed. The lens mitigates the effects of presbyopia by providing vision far through near and reduced spectacle dependence across a range of distances. The lens is intended to be placed in the capsular bag. Intraocular lenses may exacerbate an existing condition, may interfere with diagnosis or treatment of a condition or may pose an unreasonable risk to the eyesight of patients. Patients should have well-defined visual needs and be informed of the possibility of visual effects (such as halo or glare), in nighttime or poor visibility conditions. Patients may perceive these visual effects as an annoyance or hindrance, which, on rare occasions, may be significant enough for the patient to request removal of the IOL. Patients with a predicted postoperative residual astigmatism greater than 1.0 diopter, with or without a toric lens, may not fully benefit in terms of potential spectacle independence. Rotation of the TECNIS Odyssey™ Toric II IOL from its intended axis can reduce its astigmatic correction. Misalignment greater than 30° may increase postoperative refractive cylinder. If necessary, lens repositioning should occur as early as possible, prior to lens encapsulation. The lens and delivery system should be discarded if the lens has been folded within the cartridge for more than 10 minutes. Not doing so may result in the lens being stuck in the cartridge. Do not attempt to disassemble, modify, or alter the delivery system or any of its components, as this can significantly affect the function and/or structural integrity of the design. Interpret results with caution when using autorefractors or wavefront aberrometers that utilize infrared light, or when performing a duochrome test. Confirmation of refraction with maximum plus manifest refraction technique is strongly recommended. The ability to perform some eye treatments (e.g., retinal photocoagulation) may be affected by the IOL optical design. The surgeon should target emmetropia, as this lens is designed for optimum visual performance when emmetropia is achieved. The TECNIS Odyssey™ IOLs should not be placed in the ciliary sulcus. Carefully remove all viscoelastic and do not over-inflate the capsular bag at the end of the case. Residual viscoelastic and/or over-inflation of the capsular bag may allow the lens to rotate, causing misalignment of the TECNIS Odyssey™ Toric II IOL. Care should be taken to achieve centration of the toric IOL. Safety and effectiveness in patients 21 years or younger have not been established in clinical studies. ATTENTION: Reference the Directions for Use for a complete listing of Indications and Important Safety Information. INDICATIONS FOR USE The TECNIS SIMPLICITY™ Delivery System is used to fold and assist in inserting the TECNIS PureSee™ IOL which is indicated for primary implantation for the visual correction of aphakia, in adult patients with less than 1 diopter of preexisting corneal astigmatism, in whom a cataractous lens has been removed. The lens is intended to correct presbyopia by providing improved vision over a continuous range of distances including far, intermediate, and near, and decreased spectacle dependence. The lens is intended for capsular bag placement only. The TECNIS SIMPLICITY™ Delivery System is used to fold and assist in inserting the TECNIS PureSee™ Toric II IOL which is indicated for primary implantation for the visual correction of aphakia and pre-existing corneal astigmatism in adult patients with and without presbyopia in whom a cataractous lens has been removed. The lens is intended to correct presbyopia by providing improved vision over a continuous range of distances including far, intermediate, and near, a reduction of residual refractive cylinder, and decreased spectacle dependence. The lens is intended for capsular bag placement only. WARNING Physicians should weigh the potential risk/benefit ratio of IOL implantation in patients with any of the conditions described in the Directions for Use. These conditions are not specific to the design of the IOL and are attributed to cataract surgery and/or IOL implantation in general. The IOL should be placed entirely in the capsular bag. Do not place the IOL in the ciliary sulcus. Patients should be informed of the possibility of visual disturbances. The lens may cause a reduction in contrast sensitivity under certain conditions, compared to an aspheric monofocal IOL; fully inform the patient of this risk before implanting the lens. Special consideration should be made for patients with macular disease, amblyopia, corneal irregularities, or other ocular disease. Inform patients to exercise special caution when driving at night or in poor visibility conditions. Rotation of the TECNIS PureSee™ Toric II IOL away from their intended axis can reduce their astigmatic correction. Misalignment greater than 30° may increase postoperative refractive cylinder. If necessary, IOL repositioning should occur as early as possible prior to lens encapsulation. Do not attempt to disassemble, modify, or alter the delivery system, or any of its components, as this can significantly affect the function and/or structural integrity of the design. Do not use if the cartridge tip is cracked or split. Do not implant the IOL if the rod tip does not advance the IOL or if it is jammed in the delivery system. Do not advance the IOL from the Holding Position (located at the half turn rotation position for the initial advancement of the IOL into the cartridge) prior to fully hydrating the system and ready for implantation. A minimum of 1 minute at the Holding Position is required to fully hydrate the system to prevent sticking and a potential scratch or crack to the IOL. Interruptions during delivery may result in the IOL being scratched or cracked or stuck in the cartridge. Discard the device if the IOL has been advanced past the Holding Position but not delivered within 60 seconds. The IOL and delivery system should be discarded if the IOL has been folded within the cartridge for more than 10 minutes. Not doing so may result in the IOL being stuck in the cartridge. PRECAUTIONS Autorefractors may not provide optimal postoperative refraction of patients with the IOL. Manual refraction with maximum plus technique is strongly recommended. Recent contact lens usage may affect the patient's refraction; therefore, in contact lens wearers, surgeons should establish corneal stability without contact lenses prior to determining IOL power. Target emmetropia for optimum visual performance. For the TECNIS PureSee™ Toric II IOL, variability in any preoperative surgical parameters (e.g., keratometric cylinder, incision location, estimated surgically induced astigmatism, or biometry) can influence patient outcomes. Carefully remove all viscoelastic and do not over-inflate the capsular bag at the end of the case, to avoid lens rotation. This is a single use device, do not resterilize the lens or the delivery system. Do not store the device in direct sunlight or at a temperature under 5°C (41°F) or over 35°C (95°F). Do not autoclave the delivery system. Do not advance the lens unless ready for lens implantation. The contents are sterile unless the package is opened or damaged. The recommended temperature for implanting the lens is at least 17°C (63°F). The use of balanced salt solution or viscoelastics is required when using the delivery system. Do not use if the delivery system has been dropped or if any part was inadvertently struck while outside the shipping box. ADVERSE EVENTS Potential adverse events during or following cataract surgery with implantation of the IOL may include but are not limited to: Endophthalmitis/intraocular infection, IOL dislocation, persistent cystoid macular edema, persistent corneal stromal edema, persistent raised intraocular pressure (IOP) requiring treatment, secondary surgical intervention (including implant repositioning, removal, AC tap, or other surgical procedure). Adverse events can lead to permanent visual impairment and may require secondary surgical intervention, including intraocular lens exchange or explanation. ATTENTION Reference the Directions for Use for a complete listing of Indications and Important Safety Information. IN THE UNITED STATES Rx Only INDICATIONS: The TECNIS SIMPLICITY™ Delivery System is used to fold and assist in inserting the TECNIS Odyssey™ IOL, which is indicated for primary implantation for the visual correction of aphakia in adult patients, with less than 1 diopter of pre-existing corneal astigmatism, in whom a cataractous lens has been removed. The TECNIS SIMPLICITY™ Delivery System is used to fold and assist in inserting the TECNIS Odyssey™ Toric II IOLs that are indicated for primary implantation for the visual correction of aphakia and for reduction of refractive astigmatism in adult patients with greater than or equal to 1 diopter of preoperative corneal astigmatism, in whom a cataractous lens has been removed. Compared to an aspheric monofocal lens, the TECNIS Odyssey™ IOLs mitigate the effects of presbyopia by providing improved visual acuity at intermediate and near distances to reduce eyeglass wear, while maintaining comparable distance visual acuity. The lens is intended for capsular bag placement only. WARNINGS: Intraocular lenses may exacerbate an existing condition, may interfere with diagnosis or treatment of a condition or may pose an unreasonable risk to the eyesight of patients. Patients should have well-defined visual needs and be informed of possible visual effects (such as a perception of halo, starburst or glare around lights), which may be expected in nighttime or poor visibility conditions. Patients may perceive these visual effects as bothersome, which, on rare occasions, may be significant enough for the patient to request removal of the IOL. The physician should carefully weigh the potential risks and benefits for each patient. Patients with a predicted postoperative residual astigmatism greater than 1.0 diopter, with or without a toric lens, may not fully benefit in terms of reducing spectacle wear. Rotation of the TECNIS Odyssey™ Toric II IOL from its intended axis can reduce its astigmatic correction. Misalignment greater than 30° may increase postoperative refractive cylinder. If necessary, lens repositioning should occur as early as possible, prior to lens encapsulation. The lens and delivery system should be discarded if the lens has been folded within the cartridge for more than 10 minutes. Not doing so may result in the lens being stuck in the cartridge. Do not attempt to disassemble, modify, or alter the delivery system or any of its components, as this can significantly affect the function and/or structural integrity of the design. PRECAUTIONS: Interpret results with caution when using autorefractors or wavefront aberrometers that utilize infrared light, or when performing a duochrome test. Confirmation of refraction with maximum plus manifest refraction technique is strongly recommended. The ability to perform some eye treatments (e.g., retinal photocoagulation) may be affected by the IOL optical design. The surgeon should target emmetropia, as this lens is designed for optimum visual performance when emmetropia is achieved. The TECNIS Odyssey™ IOLs should not be placed in the ciliary sulcus. Carefully remove all viscoelastic and do not over-inflate the capsular bag at the end of the case. Residual viscoelastic and/or over-inflation of the capsular bag may allow the lens to rotate, causing misalignment of the TECNIS Odyssey™ Toric II IOL. All preoperative surgical parameters are important when choosing a TECNIS Odyssey™ Toric II IOL for implantation, including preoperative keratometric cylinder (magnitude and axis), incision location, the surgeon's estimated surgically induced astigmatism (SIA) and biometry. Variability in any of the preoperative measurements can influence patient outcomes and the effectiveness of treating eyes with lower amounts of preoperative corneal astigmatism. The effectiveness of TECNIS Odyssey™ Toric II IOLs in reducing postoperative residual astigmatism in patients with preoperative corneal astigmatism < 1.0 diopter has not been demonstrated. Patients with a predicted postoperative astigmatism greater than 1.0 D may not be suitable candidates for implantation with the TECNIS Odyssey™ IOLs, as they may not obtain the benefits of reduced spectacle wear or improved intermediate and near vision seen in patients with lower predicted postoperative astigmatism. ------------------------------------------------- 1 Data on File. 2024DOF4002 (prospective, multicenter, randomized, three-way-masked clinical study comparing subjects bilaterally implanted with TECNIS Synergy IOL (n=132) vs TECNIS 1-Piece Monofocal IOL (n=131) at 6-months post-op) 2 Data on File. DOF2023CT4051. 3 Data on File. 2024DOF4033 4 Data on File. DOF2019OTH4002 5 Data on File. DOF2023CT4007 6 Data on File. DOF2023CT4023 7 Data on File. 2024DOF4003 8 World report on vision. Geneva: World Health Organization, 2019. Available at: Last accessed: May 2025. 9 What Is Presbyopia – American Academy of Ophthalmology. Access from: 2024REF5075. 11 Data on File. 2024DOF4017 12 Data on File. 2024DOF4027. 13 Data on File. 2024DOF4029. 14 Data on File. 2024DOF4005 15 DOF2023CT4052 16 DOF2020CT4014 Media contact (EMEA): Sarah Smith [email protected] Media contact (NA): Maggie Lorenz [email protected] Investor contact: Sandra Easton [email protected]
Cision Canada
43 minutes ago
- Cision Canada
Market Logic launches DeepSights Agents to transform scale and speed of innovation processes
Agentic AI for Insights marks a revolutionary leap forward, systematically driving innovative product development across industries BERLIN, June 17, 2025 /CNW/ -- Market Logic, the market leading provider of insights management solutions, today announced another breakthrough for AI-driven market intelligence with the introduction of DeepSights Agents. The first agents to be released are specifically trained to identify white space opportunities, develop and refine ideas and build out robust new product concepts. By employing DeepSights Agents, companies will be able to reduce innovation cycle times by more than half. Two types of DeepSights Agents will underpin a new model for driving business impact from AI-based market intelligence technology. Together they will provide end to end support for new product-development. Always-on DeepSights Consumer Trends Agents provide enterprises with round the clock monitoring and analysis of market data. This marks a significant shift in how insights are collected and shared, moving from time intensive manual processes to proactive, fully automated processes. On-demand, goal-centric DeepSights Innovation Agents will join forces with human teams and work iteratively in a human/AI collaborative framework to deliver complex projects in a fraction of the time. These specialist AI Agent teams will be embedded within a ready to use application called DeepSights Innovation Studio. As well as on-demand Agents, the application contains customisable workflows and templates which steer users through the innovation process. "It's time to move market research and intelligence into the driving seat for growth strategies. Agentic AI presents an opportunity to make sense of market signals 24 x 7 and accelerate innovation momentum. Companies that redefine their processes to embrace these capabilities will be the ones to anticipate consumer needs and steal a march on their competition," said Olaf Lenzmann, Chief product and innovation officer, Market Logic Software. "When the pace of innovation slows, growth inevitably slows. We see the potential for DeepSights Agents to reverse this decline and enable a step-change in the volume of high-quality concepts brands bring into their innovation pipeline. Our proven ideation methodology will benefit by applying this systematic, data-driven approach to innovation process for our customers," said Richard Davies, founder, Alchemy-RX. Across industries, companies are under pressure to introduce new products to stay ahead of the competition. In Consumer-Packaged Goods (CPG), market leaders expect 10% to 20% of revenues to come from new products, in Pharmaceuticals this ratio is even higher, rising to 30%. However, many brands have fallen behind on achieving these targets because costly and difficult manual processes cannot keep up with the demands of a robust innovation pipeline. DeepSights Agents, will be in general release from August, and can be deployed across multiple industries including Pharmaceuticals, CPG, Retail, and Financial Services. Expert services support from Market Logic and its partner network will ensure optimal set up and integration of DeepSights Agents to meet the unique requirements of your market focus. Contact our experts to explore capabilities in detail: Market Logic is the leading SaaS provider of market intelligence and insights solutions. Our AI market insights platform, powered by our special purpose AI for Insights technology DeepSights, allows insights teams to equip business decisions makers with trusted insights at scale and speed. For more than 15 years, we've helped hundreds of consumer-focused brands across the globe to transform into insights-driven businesses. Market leaders such as Unilever, Vodafone, Bayer, and Tesco are driving innovation and making smarter market moves with the support of Market Logic.
Canada Standard
2 hours ago
- Canada Standard
"More money in trade with India than there is with Pakistani proxy, propped up by China": Canadian journalist Daniel Bordman's on PM Modi's visit, Sikh extremism
Calgary [Canada], June 17 (ANI): Canadian journalist Daniel Bordman shed light on the visit of Prime Minister Narendra Modi's to attend the 51st G7 Summit in Kananaskis, Alberta amid the complex dynamics between India and Canada, particularly regarding the Sikh extremist. Bordman described the visit as a 'significant' development with implications for domestic politics, trade, and the country's handling of extremism. Bordman said that the Khalistan movement is a significant obstacle in India-Canada relations. He asserted that Canada's leniency towards Sikh separatist groups operating in Canada, allegedly funded by Pakistan, is perceived as support for terrorism and balkanization by India. 'It is pretty significant for Canada because, for the last 10 years, Canadian politics has been defined externally by chaos and bad actors, and internally by buffoonery... Canadians are happy to have a Prime Minister who speaks in full sentences and counts to ten without his fingers...,' said Bordman. Bordman views this development as a positive step towards counter-radicalization in Canada. He criticisesed the current liberal government's approach, suggesting that economic interests should take precedence over supporting groups that undermine nation-states. 'The major sticking point that Canada and India had is the Khalistan movement and the support of outright terrorism and balkanisation in the country... No one wants India to go through internal separation again, but there is a push outside of India to undermine it, mostly funded by Pakistan. All the groups who want to destroy India are the same who want to destroy Israel and America -- they undermine the concept of a nation-state... Canada has become a hub of all these bad actors...,' said Bordman. Bordman views PM Modi's visit as a turning point in Canada's approach to the Khalistan issue. He said that by engaging with India, Canada is distancing itself from its previous permissive stance towards terrorists and separatists. 'By inviting PM Modi, it is a pretty hard shift for Mark Carney to distance the liberal brand from the permissive of terrorists and separatists... This is a good first step to counter-radicalisation... We are at the maximum Khalistani nonsense in Canada, with a liberal close inner circle in the cabinet, propped up by Jagmeet Singh's NDP... The biggest Khalistani power display is in Surrey right now... The Khalistani menace seems to be toned down because Mark Carney is an economist... There is more money in trade with India, a real country with billions of people, than there is with a Pakistani proxy, propped up by China, who run around and run drugs for the country... We have everything India needs, and India has a huge consumer base...,' added the Canadian journalist. Bordman highlighted the economic costs of not addressing the Khalistan issue, citing the potential harm to Canada's credibility and trade relationships with other countries, including India. He noted that India is a significant market with a huge consumer base, making it an attractive trade partner. Further elaborating on the implications of the visit, Bordman said, '... The crackdown on Khalistan and trade with India are linked. Canada's trade with every other country is linked to the same thing. Suppose you have a transnational criminal organisation in your ports and running logistics in your country, like the Khalistanis run drugs through the truck industry. In that case, it poses a real problem economically and trade-wise... If Canada wants to be a player on the world stage, we need to do something about Khalistan because these people are significantly harming Canada in the social fabric and also have a huge economic cost... Their involvement in our system will reduce our credibility in countries that want to trade with us...' PM Modi's visit to Canada comes after a period of friction between New Delhi and Ottawa, triggered by Canadian allegations that Indian agents were involved in the killing of NIA-designated terrorist Hardeep Singh Nijjar outside a gurdwara in Canada in 2023. India had strongly rejected the allegations. The diplomatic standoff escalated as both countries expelled senior diplomats in a tit-for-tat response. New Delhi has consistently voiced concerns about extremism and anti-India activities on Canadian soil and urged Canadian authorities to take concrete steps to curb such elements. This visit is part of PM Modi's three-nation official tour, which began with Cyprus and will conclude with Croatia. The G7 Summit, which PM Modi is set to attend on June 16-17, is an annual gathering of leaders from the United States, United Kingdom, France, Germany, Japan, Italy, Canada, and the European Union (EU). This marks PM Modi's sixth consecutive participation in the G7 Summit. (ANI)
